Related references
Note: Only part of the references are listed.Impact of electrochemotherapy in metastatic cutaneous melanoma: a contemporary systematic review and meta-analysis
Fausto Petrelli et al.
ACTA ONCOLOGICA (2022)
BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma
Janice M. Mehnert et al.
CLINICAL CANCER RESEARCH (2022)
Conjugate of ibrutinib with a TLR7 agonist suppresses melanoma progression and enhances antitumor immunity
Sumei Ren et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2022)
Stereotactic radiosurgery with immunotherapy is associated with improved overall survival in patients with metastatic melanoma or non-small cell lung cancer: a National Cancer Database analysis
J. M. Jiang et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2022)
Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma
Nikolaj Pagh Kristensen et al.
JOURNAL OF CLINICAL INVESTIGATION (2022)
Melanoma cells can be eliminated by sialylated CD43 x CD3 bispecific T cell engager formats in vitro and in vivo
G. de Jong et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial
Amita Patnaik et al.
CLINICAL CANCER RESEARCH (2021)
Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma
Zhuting Hu et al.
NATURE MEDICINE (2021)
Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
Erez N. Baruch et al.
SCIENCE (2021)
Preclinical development of CD126 CAR-T cells with broad antitumor activity
Ameet K. Mishra et al.
BLOOD CANCER JOURNAL (2021)
Mutations in the IFNγ-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment
Tan-Trieu Nguyen et al.
CLINICAL CANCER RESEARCH (2021)
Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma
Caroline Robert et al.
EUROPEAN JOURNAL OF CANCER (2021)
Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2
Joseph Clark et al.
JOURNAL OF INVESTIGATIVE MEDICINE (2021)
mRNA in cancer immunotherapy: beyond a source of antigen
Lien Van Hoecke et al.
MOLECULAR CANCER (2021)
Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma
E. A. Rozeman et al.
NATURE MEDICINE (2021)
Cytokine-Coding Oncolytic Adenovirus TILT-123 Is Safe, Selective, and Effective as a Single Agent and in Combination with Immune Checkpoint Inhibitor Anti-PD-1
Riikka Havunen et al.
CELLS (2021)
Phase I-II Open-Label Multicenter Study of Palbociclib plus Vemurafenib in BRAFV600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism
Baptiste Louveau et al.
CLINICAL CANCER RESEARCH (2021)
Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma
Walter J. Storkus et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
PHARMACOKINETICS OF FIRST AND REPEATED DOSING OF NON-IRAE-INDUCING ANTI-CTLA-4 MONOCLONAL ANTIBODY ONC-392 IN ADVANCED CANCER PATIENTS
Hung-Yen Chou et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
REMOVAL OF SOLUBLE TUMOR NECROSIS FACTORS RECEPTORS 1/2 IN PATIENTS WITH METASTATIC SOLID TUMORS USING IMMUNE APHERESIS
Ayala Tamir et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma
Amod A. Sarnaik et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
mRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients
Maryam Bidram et al.
VACCINES (2021)
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
Alexander M. M. Eggermont et al.
LANCET ONCOLOGY (2021)
Loss of Ambra1 promotes melanoma growth and invasion
Luca Di Leo et al.
NATURE COMMUNICATIONS (2021)
Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors
Antoine Hollebecque et al.
CLINICAL CANCER RESEARCH (2021)
Impact of Prior Treatment on the Efficacy of Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma
Samantha J. Seitter et al.
CLINICAL CANCER RESEARCH (2021)
Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules
Georgina Long et al.
CLINICAL CANCER RESEARCH (2021)
Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma
Robert H. I. Andtbacka et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).
Evan J. Lipson et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
The role of regional chemotherapy for advanced limb melanoma in the era of potentially effective systemic therapies
Rebecca L. Read et al.
MELANOMA RESEARCH (2021)
Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund's adjuvant (IFA) for resected high-risk melanoma
Sapna P. Patel et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Harnessing the immune system to fight cancer with Toll-like receptor and RIG-I-like receptor agonists
Carole Bourquin et al.
PHARMACOLOGICAL RESEARCH (2020)
Combined NK Cell Therapy and Radiation Therapy Exhibit Long-Term Therapeutic and Antimetastatic Effects in a Human Triple Negative Breast Cancer Model
Kyung Won Kim et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2020)
Comparative-effectiveness of pembrolizumab vs. nivolumab for patients with metastatic melanoma
Justin C. Moser et al.
ACTA ONCOLOGICA (2020)
Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma
Paolo A. Ascierto et al.
EUROPEAN JOURNAL OF CANCER (2020)
A TLR7 agonist strengthens T and NK cell function during BRAF-targeted therapy in a preclinical melanoma model
Lydia Bellmann et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Mechanistic insights into cancer cell killing through interaction of phosphodiesterase 3A and schlafen family member 12
Xiaoyun Wu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2020)
HX008: a humanized PD-1 blocking antibody with potent antitumor activity and superior pharmacologic properties
Jibin Zhang et al.
MABS (2020)
The repertoire of mutational signatures in human cancer
Ludmil B. Alexandrov et al.
NATURE (2020)
A large peptidome dataset improves HLA class I epitope prediction across most of the human population
Siranush Sarkizova et al.
NATURE BIOTECHNOLOGY (2020)
PD-L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study
Muhammad A. Khattak et al.
ONCOLOGIST (2020)
Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist
Giulia Parisi et al.
NATURE COMMUNICATIONS (2020)
Adoptive cell transfer (ACT) of autologous tumor-infiltrating lymphocytes (TILs) to treat malignant melanoma: the dawn of a chimeric antigen receptor T (CAR-T) cell therapy from autologous donor
Luca Roncati et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2020)
Systemic Therapy for Melanoma: ASCO Guideline
Rahul Seth et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
EZH2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma
Jessamy Tiffen et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2020)
Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition
Jenny H. Lee et al.
NATURE COMMUNICATIONS (2020)
Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial
Lisa Zimmer et al.
LANCET (2020)
Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B
Matteo S. Carlino et al.
CLINICAL CANCER RESEARCH (2020)
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
Ralf Gutzmer et al.
LANCET (2020)
Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction
Daniel K. Wells et al.
CELL (2020)
Toxicity in combination immune checkpoint inhibitor and radiation therapy: A systematic review and meta-analysis
Congzhou M. Sha et al.
RADIOTHERAPY AND ONCOLOGY (2020)
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
Reinhard Dummer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Combination of TYRP1-TCB, a novel T cell bispecific antibody for the treatment of melanoma, with immunomodulatory agents
Valeria G. Nicolini et al.
CANCER RESEARCH (2020)
RG7769 (PD1-TIM3), a novel heterodimeric avidity-driven T cell specific PD-1/TIM-3 bispecific antibody lacking Fc-mediated effector functions for dual checkpoint inhibition to reactivate dysfunctional T cells
Laura Laura et al.
CANCER RESEARCH (2020)
Combination of Photodynamic Therapy and a Flagellin-Adjuvanted Cancer Vaccine Potentiated the Anti-PD-1-Mediated Melanoma Suppression
Hye Suk Hwang et al.
CELLS (2020)
Near-infrared absorbing Ru(ii) complexes act as immunoprotective photodynamic therapy (PDT) agents against aggressive melanoma
Liubov M. Lifshits et al.
CHEMICAL SCIENCE (2020)
Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors
Meijia Yang et al.
THERANOSTICS (2020)
Highly efficient singlet oxygen generation, two-photon photodynamic therapy and melanoma ablation by rationally designed mitochondria-specific near-infrared AIEgens
Zheng Zheng et al.
CHEMICAL SCIENCE (2020)
A Phase 1 Trial of Oncolytic Adenovirus ICOVIR-5 Administered Intravenously to Cutaneous and Uveal Melanoma Patients
Margarita Garcia et al.
HUMAN GENE THERAPY (2019)
Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response
J. E. Stein et al.
ANNALS OF ONCOLOGY (2019)
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
O. Hamid et al.
ANNALS OF ONCOLOGY (2019)
Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial
Celeste Lebbe et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma
Alexander C. Huang et al.
NATURE MEDICINE (2019)
Two roads for oncolytic immunotherapy development
Howard L. Kaufman et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition
Elizabeth I. Buchbinder et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
CA045-001: A phase Ill, randomized, open label study of bempegaldesleukin (NKTR-214) plus nivolumab (NIVO) versus NIVO monotherapy in patients (pts) with previously untreated, unresectable or metastatic melanoma (MEL).
Nikhil I. Khushalani et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A phase I study of a novel MDM2 antagonist APG-115 in patients with advanced solid tumors.
Drew W. Rasco et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Prognostic value of tumor-infiltrating lymphocytes in melanoma: a systematic review and meta-analysis
Qiaofen Fu et al.
ONCOIMMUNOLOGY (2019)
Diverse Mechanisms of BRAF Inhibitor Resistance in Melanoma Identified in Clinical and Preclinical Studies
Stephen A. Luebker et al.
FRONTIERS IN ONCOLOGY (2019)
Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy
Yan Zhang et al.
CELL RESEARCH (2019)
Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium
Rodabe N. Amaria et al.
LANCET ONCOLOGY (2019)
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Caroline Robert et al.
LANCET ONCOLOGY (2019)
Real-world experience with pembrolizumab in patients with advanced melanoma A large retrospective observational study
Frank Xiaoqing Liu et al.
MEDICINE (2019)
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
Paolo Antonio Ascierto et al.
NATURE MEDICINE (2019)
Photodynamic therapy of melanoma by blue-light photoactivation of flavin mononucleotide
R. A. Akasov et al.
SCIENTIFIC REPORTS (2019)
Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial
Alexander M. M. Eggermont et al.
EUROPEAN JOURNAL OF CANCER (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Ocular preservation through limited tumor excision combined with ALA-PDT in patients with periocular basal cell carcinoma
Xinying Li et al.
PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY (2019)
Management of cytokine release syndrome related to CAR-T cell therapy
Hongli Chen et al.
FRONTIERS OF MEDICINE (2019)
Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis
U. Dafni et al.
ANNALS OF ONCOLOGY (2019)
Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm
Neta Tsur et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2019)
MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment
Douglas D. Fang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma
Omid Hamid et al.
CANCERS (2019)
Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma
Pok Fai Wong et al.
CLINICAL CANCER RESEARCH (2019)
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert M. Samstein et al.
NATURE GENETICS (2019)
Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model
Lukasz Kuryk et al.
ONCOIMMUNOLOGY (2019)
Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor
Elisa Ruffo et al.
SEMINARS IN IMMUNOLOGY (2019)
Safety and immunogenicity of a personalized neoantigen-Listeria vaccine in cancer patients
J. Randolph Hecht et al.
CANCER RESEARCH (2019)
Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practice
C. Lance Cowey et al.
JOURNAL OF IMMUNOTHERAPY (2018)
Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine
Liang Cheng et al.
MODERN PATHOLOGY (2018)
Mechanisms of resistance to immune checkpoint inhibitors
Russell W. Jenkins et al.
BRITISH JOURNAL OF CANCER (2018)
Phase I trial of Lipovaxin-MM, a novel dendritic cell-targeted liposomal vaccine for malignant melanoma
Tessa Gargett et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome
Marie-Andree Forget et al.
CLINICAL CANCER RESEARCH (2018)
Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
Linda Chen et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2018)
STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network
Julie Delyon et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
Reinhard Dummer et al.
LANCET ONCOLOGY (2018)
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Lesion oxygenation associates with clinical outcomes in premalignant and early stage head and neck tumors treated on a phase 1 trial of photodynamic therapy
Peter H. Ahn et al.
PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY (2018)
Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes
Jonathan T. Sockolosky et al.
SCIENCE (2018)
The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma
Janine Kimpel et al.
VIRUSES-BASEL (2018)
Anti-Melanoma immunity and local regression of cutaneous metastases in melanoma patients treated with monobenzone and imiquimod; a phase 2 a trial
Hansje-Eva Teulings et al.
ONCOIMMUNOLOGY (2018)
The Partnership for Accelerating Cancer Therapies
Rebecca G. Baker et al.
CANCER JOURNAL (2018)
Resiquimod, a Toll-like receptor agonist promotes melanoma regression by enhancing plasmacytoid dendritic cells and T cytotoxic activity as a vaccination adjuvant and by direct tumor application
Jorge A. Borin Scutti et al.
CANCER RESEARCH (2018)
NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT.
Adi Diab et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Photodynamic Therapy for Metastatic Melanoma Treatment: A Review
Channay Naidoo et al.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT (2018)
MicroRNAs Enable mRNA Therapeutics to Selectively Program Cancer Cells to Self-Destruct
Ruchi Jain et al.
NUCLEIC ACID THERAPEUTICS (2018)
Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma
Diwakar Davar et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
Frank Stephen Hodi et al.
LANCET ONCOLOGY (2018)
Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
Christian U. Blank et al.
NATURE MEDICINE (2018)
The diverse functions of the PD1 inhibitory pathway
Arlene H. Sharpe et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Combining radiotherapy and ipilimumab induces clinically relevant radiation-induced abscopal effects in metastatic melanoma patients: A systematic review
Rodolfo Chicas-Sett et al.
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY (2018)
Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma
Lisa Zimmer et al.
EUROPEAN JOURNAL OF CANCER (2017)
Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis
Natalie J. Ives et al.
EUROPEAN JOURNAL OF CANCER (2017)
Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy
Andrew Bang et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy
Erhao Zhang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Photodynamic therapy mediated by acai oil (Euterpe oleracea Martius) in nanoemulsion: A potential treatment for melanoma
Victoria Monge-Fuentes et al.
JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY (2017)
Melanoma subtypes demonstrate distinct PD-L1 expression profiles
Genevieve J. Kaunitz et al.
LABORATORY INVESTIGATION (2017)
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Jacob Schachter et al.
LANCET (2017)
Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial
Georgina V. Long et al.
LANCET ONCOLOGY (2017)
Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combination
Amelie Aboudaram et al.
MELANOMA RESEARCH (2017)
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Aaron M. Goodman et al.
MOLECULAR CANCER THERAPEUTICS (2017)
An immunogenic personal neoantigen vaccine for patients with melanoma
Patrick A. Ott et al.
NATURE (2017)
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma
Martin Lauss et al.
NATURE COMMUNICATIONS (2017)
Ambra1 spatially regulates Src activity and Src/FAK-mediated cancer cell invasion via trafficking networks
Christina Schoenherr et al.
ELIFE (2017)
High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute
Diwakar Davar et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment
Erik S. Anderson et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Adoptive Cell Therapy for Metastatic Melanoma
Efrat Merhavi-Shoham et al.
CANCER JOURNAL (2017)
Effect of a novel IL-2 cytokine immune agonist (NKTR-214) on proliferating CD8+T cells and PD-1 expression on immune cells in the tumor microenvironment in patients with prior checkpoint therapy.
Chantale Bernatchez et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial
J. Guo et al.
ANNALS OF ONCOLOGY (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
First oncolytic virus approved for melanoma immunotherapy
Jonathan Pol et al.
ONCOIMMUNOLOGY (2016)
Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases
Ileana S. Mauldin et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Benjamin Weide et al.
CLINICAL CANCER RESEARCH (2016)
Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: Single centre subset analysis from a phase 1/2 trial
Antonin Levy et al.
EUROPEAN JOURNAL OF CANCER (2016)
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Antoni Ribas et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma
Stephanie L. Goff et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
F. Stephen Hodi et al.
LANCET ONCOLOGY (2016)
Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2016)
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
Shohei Koyama et al.
NATURE COMMUNICATIONS (2016)
Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
Jing Liu et al.
CANCER DISCOVERY (2016)
Activated dendritic cells delivered in tissue compatible biomatrices induce in-situ anti-tumor CTL responses leading to tumor regression
Vivek Verma et al.
ONCOTARGET (2016)
Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma
E. Liniker et al.
ONCOIMMUNOLOGY (2016)
Immunological quality and performance of tumor vessel-targeting CAR-T cells prepared by mRNA-EP for clinical research
Kanako Inoo et al.
MOLECULAR THERAPY-ONCOLYTICS (2016)
The prognostic significance of stable disease following high-dose interleukin-2 (IL-2) treatment in patients with metastatic melanoma and renal cell carcinoma
Tasha Hughes et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
Sonja Kleffel et al.
CELL (2015)
Overall survival in patients with metastatic melanoma
Xue Song et al.
CURRENT MEDICAL RESEARCH AND OPINION (2015)
UPDATED CLINICAL EFFICACY OF THE ANTI-PD-1 MONOCLONAL ANTIBODY PEMBROLIZUMAB (MK-3475) IN 411 PATIENTS WITH MELANOMA
A. Ribas et al.
EUROPEAN JOURNAL OF CANCER (2015)
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H. I. Andtbacka et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Dirk Schadendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Christina Twyman-Saint Victor et al.
NATURE (2015)
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Stefani Spranger et al.
NATURE (2015)
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Adoptive cell transfer as personalized immunotherapy for human cancer
Steven A. Rosenberg et al.
SCIENCE (2015)
Immune Escape Mechanisms as a Guide for Cancer Immunotherapy
Gregory L. Beatty et al.
CLINICAL CANCER RESEARCH (2015)
Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen
Andrew B. Sharabi et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Oncolytic Viruses: Exploiting Cancer's Deal with the Devil
Larissa A. Pikor et al.
TRENDS IN CANCER (2015)
Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations
Michaela Angelika Ihle et al.
BMC CANCER (2014)
The MAPK Pathway Across Different Malignancies: A New Perspective
Mauricio Burotto et al.
CANCER (2014)
BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
Helen Rizos et al.
CLINICAL CANCER RESEARCH (2014)
Targeting the PD1/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities
Barbara Merelli et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2014)
Factors associated with response, survival, and limb salvage in patients undergoing isolated limb infusion
Jonathan Steinman et al.
JOURNAL OF SURGICAL ONCOLOGY (2014)
Isolated Limb Perfusion with Melphalan for Melanoma
Omgo E. Nieweg et al.
JOURNAL OF SURGICAL ONCOLOGY (2014)
Isolated Limb Perfusion for In-Transit Melanoma Metastases: Melphalan or TNF-Melphalan Perfusion?
Harald J. Hoekstra et al.
JOURNAL OF SURGICAL ONCOLOGY (2014)
Isolated Limb Infusion with Melphalan and Actinomycin D for Melanoma: A Systematic Review
Hidde M. Kroon et al.
JOURNAL OF SURGICAL ONCOLOGY (2014)
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
James Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade
Ines Pires da Silva et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas
Muhammad Baghdadi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
The Abscopal Effect Associated With a Systemic Anti-melanoma Immune Response
Emily F. Stamell et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2013)
Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
Antoni Ribas et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
F. Stephen Hodi et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Listeria monocytogenes (Lm)-LLO Immunotherapies Reduce the Immunosuppressive Activity of Myeloid-derived Suppressor Cells and Regulatory T Cells in the Tumor Microenvironment
Anu Wallecha et al.
JOURNAL OF IMMUNOTHERAPY (2013)
At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
Andrew M. Intlekofer et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2013)
Frequency and Spectrum of BRAF Mutations in a Retrospective, Single-Institution Study of 1112 Cases of Melanoma
Wesley O. Greaves et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2013)
Paradoxical oncogenesis-the long-term effects of BRAF inhibition in melanoma
Geoffrey T. Gibney et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
An immune-active tumor microenvironment favors clinical response to ipilimumab
Rui-Ru Ji et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Ipilimumab and Stereotactic Radiosurgery for Melanoma Brain Metastases
A. P. Kiess et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma
Alexander M. M. Eggermont et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
IFN-α in the Treatment of Melanoma
Ahmad A. Tarhini et al.
JOURNAL OF IMMUNOLOGY (2012)
Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients
Eva Ellebaek et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
The role of BRAF V600 mutation in melanoma
Paolo A. Ascierto et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al.
LANCET (2012)
Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'
Aron M. Levin et al.
NATURE (2012)
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
Janis M. Taube et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Phase 1 Study of Stereotactic Body Radiotherapy and Interleukin-2: Tumor and Immunological Responses
Steven K. Seung et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Whole Cell Vaccines-Past Progress and Future Strategies
Bridget P. Keenan et al.
SEMINARS IN ONCOLOGY (2012)
Overall Survival and PD-L1 Expression in Metastasized Malignant Melanoma
Jules Gadiot et al.
CANCER (2011)
Viral Vector-Based Therapeutic Cancer Vaccines
Cecilia Larocca et al.
CANCER JOURNAL (2011)
The Efficacy of Radiotherapy Relies upon Induction of Type I Interferon-Dependent Innate and Adaptive Immunity
Byron C. Burnette et al.
CANCER RESEARCH (2011)
Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
Steven A. Rosenberg et al.
CLINICAL CANCER RESEARCH (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
γ-Radiation Promotes Immunological Recognition of Cancer Cells through Increased Expression of Cancer-Testis Antigens In Vitro and In Vivo
Anu Sharma et al.
PLOS ONE (2011)
Tumor Cell Expression of Programmed Cell Death-1 Ligand 1 Is a Prognostic Factor for Malignant Melanoma
Ryosuke Hino et al.
CANCER (2010)
Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-α 2b treatment
Paolo A. Ascierto et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment
Youjin Lee et al.
BLOOD (2009)
Intratumoral Immune Cell Infiltrates, FoxP3, and Indoleamine 2,3-Dioxygenase in Patients with Melanoma Undergoing CTLA4 Blockade
Antoni Ribas et al.
CLINICAL CANCER RESEARCH (2009)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
Jeffrey Weber et al.
CLINICAL CANCER RESEARCH (2009)
Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells
Robert Besch et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: Expert opinion
Axel Hauschild et al.
CANCER (2008)
Radiation-induced IFN-γ production within the tumor microenvironment influences antitumor immunity
Amit A. Lugade et al.
JOURNAL OF IMMUNOLOGY (2008)
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma:: final results of EORTC 18991, a randomised phase III trial
Alexander M. M. Eggermont et al.
LANCET (2008)
Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma
D. S. Green et al.
BRITISH JOURNAL OF DERMATOLOGY (2007)
Induced sensitization of tumor stroma leads to eradication of established cancer by T cells
Bin Zhang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2007)
Increase of NKAG2D ligands and sensitivity to NK cell-mediated cytotoxicity of tumor cells by heat shock and ionizing radiation
Joo-Young Kim et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2006)
Photodynamic therapy and anti-tumour immunity
Ana P. Castano et al.
NATURE REVIEWS CANCER (2006)
Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-α2b in metastatic melanoma
E Bajetta et al.
ANNALS OF ONCOLOGY (2006)
Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade
AV Maker et al.
JOURNAL OF IMMUNOLOGY (2005)
A phase II trial of tow-dose total body irradiation and subcutaneous interleukin-2 in metastatic melanoma
A Safwat et al.
RADIOTHERAPY AND ONCOLOGY (2005)
Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor
AA Lugade et al.
JOURNAL OF IMMUNOLOGY (2005)
A pooled analysis of Eastern Cooperative Oncology Group and Intergroup trials of adjuvant high-dose interferon for melanoma
JM Kirkwood et al.
CLINICAL CANCER RESEARCH (2004)
Ionizing radiation affects human MART-1 melanoma antigen processing and presentation by dendritic cells
YP Liao et al.
JOURNAL OF IMMUNOLOGY (2004)
Interferon alpha as adjuvant postsurgical treatment of melanoma: A meta-analysis
D Pirard et al.
DERMATOLOGY (2004)
Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes
CT Garnett et al.
CANCER RESEARCH (2004)
Does adjuvant interferon-α for high-risk melanoma provide a worthwhile benefit?: A meta-analysis of the randomised trials
K Wheatley et al.
CANCER TREATMENT REVIEWS (2003)
Concurrent interferon-α and radiation for head and neck melanoma
NP Nguyen et al.
MELANOMA RESEARCH (2003)
Immunomodulatory effects of high-dose and lowdose interferon α2b in patients with high-risk resected melanoma -: The E2690 laboratory corollary of Intergroup Adjuvant Trial E1690
JM Kirkwood et al.
CANCER (2002)
The interaction properties of costimulatory molecules revisited
AV Collins et al.
IMMUNITY (2002)
Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: Overall results of a randomized trial of the Southwest Oncology Group
VK Sondak et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Combined adjuvant radiation and interferon-alpha 2B therapy in high-risk melanoma patients: The potential for increased radiation toxicity
LJ Hazard et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2002)
Share Paper
